Supporting our findings, armed MSC-sTRAIL enhance the therapeutic response to paclitaxel and AKTi in PDAC [41, 56], HDAC inhibitors in glioma [42], radiotherapy [20, 23, 25, 27, 39, 57, 58] and immunotherapy [59]. This evidence concerns the gene HDAC9 and central nervous system cancer.